7 completed, 1 terminated, 1 unknown. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hemophilia: new trials by email Literature Review of Hemophilia trials Research Report on Hemophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 25 | 2024-03-18 | 2025-01-22 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 32 | 2023-01-09 | 2024-01-02 |
| KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ - Hemophilia | Phase 2 | Completed | Suzhou Alphamab Co., Ltd. | 24 | 2022-07-07 | 2024-12-30 |
| Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial. Sodium valproate extended-release tablets - Hemophilia | Phase 1 / Phase 2 | Unknown | Xue-chun Lu | 10 | 2022-04-01 | 2024-02-29 |
| A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor STSP-0601 for Injection - Hemophilia | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 77 | 2021-10-12 | 2024-09-19 |
| Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Fitusiran - Hemophilia | Phase 2 / Phase 3 | Completed | Genzyme, a Sanofi Company | 32 | 2020-01-28 | 2026-09-28 |
| Weight-based Dosing in Hemophilia A rFVIII - Hemophilia | Phase 2 | Terminated | Craig Seaman | 30 | 2015-09-01 | 2020-09-25 |
| Treatment of Hepatitis C in Hemophilic Patients With HIV Peginterferon alfa-2a, Ribavirin - HIV Infections, Hepatitis C | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2002-03-01 | 2008-07-30 |
Hemophilia A (9) · HIV Infections (1) · Hepatitis C (1)
Blood Coagulation Disorders (9) · Blood Coagulation Disorders, Inherited (9) · Coagulation Protein Disorders (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Blood-Borne Infections (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Flaviviridae Infections (1) · Genital Diseases (1) · Hepatitis (1) · Hepatitis, Viral, Human (1)
Injections (3) · Calcitriol (1) · F8 protein, human (1) · Factor VIII (1) · Ribavirin (1) · Sirolimus (1) · factor VIII-Fc fusion protein (1) · fitusiran (1) · peginterferon alfa-2a (1)
Staidson (Beijing) Biopharmaceuticals Co., Ltd (3) · Craig Seaman (1) · Genzyme, a Sanofi Company (1) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Suzhou Alphamab Co., Ltd. (1) · Xue-chun Lu (1)
China (6) · United States (3) · Canada (1) · India (1) · Italy (1) · Spain (1) · Turkey (Türkiye) (1)
Lei Zhang, Ph.D (2) · Changcheng Zheng, Doctor (1) · Craig Seaman, MD, MS (1) · Hu Zhou, Doctor (1) · Jing Sun, Doctor (1) · Kenneth E. Sherman, MD, PhD (1) · Lei Zhang, MD (1) · Renchi Yang, Doctor (1) · Shujie Wang, Doctor (1) · Xielan Zhao, Doctor (1) · Xuechun Lu, M.D. (1) · Ziqiang Yu, Doctor (1)
PMID 41637644, PMID 15374882, PMID 17058240, PMID 17090654, PMID 19127265, PMID 22149959, PMID 23855900, PMID 23863832, PMID 27392538, PMID 29224506, PMID 31011710, PMID 36796484
2019 (1), R01AI049508 (1)